lymphoid leukemia (Cancer)
Information
- Disease name
- lymphoid leukemia
- Disease ID
- DOID:1037
- Description
- "A leukemia that has_material_basis_in a B-cell or T-cell lineage involving primarily the bone marrow and the peripheral blood." [url:http\://www.cancer.gov/dictionary?CdrID=616067]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04472286 | Active, not recruiting | Healthy Bones, Healthy Life: Habitual Physical Activity on Bone & Metabolic Health in Pediatric Cancer Survivors | November 1, 2020 | May 30, 2024 | |
| NCT00683046 | Completed | Phase 2 | T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies | November 2001 | December 2014 |
| NCT00469729 | Completed | Phase 2/Phase 3 | Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy | October 2007 | June 2015 |
| NCT01754857 | Completed | Phase 2 | Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL | November 12, 2013 | June 30, 2022 |
| NCT02593123 | Completed | Phase 2 | Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis | November 4, 2015 | March 18, 2022 |
| NCT02719821 | Completed | N/A | Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplantation | March 2016 | June 2, 2017 |
| NCT02955043 | Completed | N/A | Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery | December 22, 2016 | October 26, 2018 |
| NCT03575325 | Completed | Phase 2 | Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia | October 11, 2018 | September 14, 2023 |
| NCT03613727 | Completed | Phase 2 | Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients | October 1, 2018 | October 6, 2022 |
| NCT05865301 | Not yet recruiting | Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy | August 30, 2024 | August 30, 2024 | |
| NCT05507827 | Recruiting | Phase 1 | Safety of Myeloablative Conditioning, Orca-T, and Allogeneic, Donor-Derived CD19/CD22-CAR (Chimeric Antigen Receptor) T Cells in Adults With B-cell Acute Lymphoblastic Leukemia (ALL) | August 18, 2022 | January 2037 |
| NCT05871008 | Recruiting | N/A | Integrated Actionable Aging Assessment for Cancer Patients Pilot | March 1, 2024 | December 2026 |
| NCT02462265 | Suspended | Phase 2 | Oshadi D & Oshadi R Combined With Salvage Chemotherapy for Relapsed Acute Myeloid Leukemia or Lymphoid Leukemia Patients | January 2017 | December 2018 |
| NCT04155840 | Terminated | Phase 2 | Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | January 31, 2020 | March 16, 2021 |
| NCT01643603 | Terminated | Phase 1 | Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies | May 2012 | October 9, 2018 |
| NCT00801580 | Unknown status | Phase 2 | My-HyperCVAD in the Treatment of Relapsed Refractory Adult Acute Lymphoid Leukemia | March 2008 | September 2010 |
- Disase is a (Disease Ontology)
- DOID:1240
- Cross Reference ID (Disease Ontology)
- ICD10CM:C91
- Cross Reference ID (Disease Ontology)
- ICD9CM:204
- Cross Reference ID (Disease Ontology)
- ICDO:9820/3
- Cross Reference ID (Disease Ontology)
- MESH:D007945
- Cross Reference ID (Disease Ontology)
- NCI:C7539
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:93170002
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0023448
- Exact Synonym (Disease Ontology)
- lymphoblastic leukaemia
- Exact Synonym (Disease Ontology)
- lymphoblastic leukemia
- Exact Synonym (Disease Ontology)
- lymphocytic leukaemia
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0005526